Editorial

Neuralink and Synchron: The Billionaire Battle of the Brain Chip
Editorial Neuralink and Synchron: The Billionaire Battle of the Brain Chip

Elon Musk. Jeff Bezos. Bill Gates. These three men have a lot in common. They’re all tech founders who have disrupted their respective industries and cemented their place in the annals of history for their global (and extra-terrestrial) dominance. Between them, they have a combined net worth of

Precision Medicine With Additive Manufacturing
Editorial Precision Medicine With Additive Manufacturing

Additive manufacturing (AM) and 3D printing came into the tech scene as some of the most disruptive technologies, indicating that we are on the precipice of the fourth industrial revolution. These advancements have affected pharmaceutical market growth, which has expanded by 17% annually between

A Look Inside the Global Biopharmaceutical Supply Chain
Editorial A Look Inside the Global Biopharmaceutical Supply Chain

Welcome to the land of biopharmaceuticals, where the wonders of medicine meet with the intricacies of distribution networks. The biopharma sector is blazing a trail in creating life-saving medications, vaccines, and treatments. These aren’t merely commodities, they serve as support for individuals

Fierce JPM Week: A Roundup of Biopharma’s Biggest Week
Editorial Fierce JPM Week: A Roundup of Biopharma’s Biggest Week

For the biopharma industry, the start of the year holds one of the biggest events in the global industry calendar, JPM Week. It’s the ultimate meeting of minds, bringing together scientists, pharmaceutical industry professionals, bankers, investors, startup founders, journalists, and media. It sets

The A-Z of AstraZeneca’s Billion Dollar Acquisition
Editorial The A-Z of AstraZeneca’s Billion Dollar Acquisition

With a $1.2 billion dollar acquisition of Gracell Biotechnologies, pharmaceutical giant AstraZeneca has firmly entrenched itself in the Asian market. The company is not only expanding its footprint, but also broadening its scope with its foray into cell therapy—Gracell’s specialized offering. With

The FDA grants accelerated approval for Pfizer’s Elrexfio
Editorial The FDA grants accelerated approval for Pfizer’s Elrexfio

For patients living with Relapsed or Refractory Multiple Myeloma (RRMM), life revolves around treatment cycles, clinical trials, brief periods of good health, and the uncertainty of when they will be sick again. By definition, RRMM is a rare type of incurable blood cancer referred to as relapsed

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later